Business
Oxford BioMedica (OXB): Gene-therapy for Parkin...
Oxford BioMedica (OXB): Gene-therapy for Parkin....
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression14-Jun-2018 / 09:50 GMT/BST\nHardman & Co Research: Gene-therapy for Parkinson's: clinical progression\n\nOXB is a specialist advanced-therapy lentivirus vector biopharma company. It offers vector manufacturing and development services, and also has a proprietary drug pipeline. In addition to LentiVector(R) service contracts, OXB receives royalties on commercial therapies developed by its partners using the LentiVector platform. A partnership deal structure was established with Novartis for KymriahPPPTM in 2017,PP and was followed by a collaboration and licence agreement with Bioverativ Inc in February 2018. The latest deal, on 6 June 2018, is the first involving OXB's proprietary platform: it will advance the Parkinson's disease gene-therapy to the clinic. Please click here for the full report:\n\nhttp://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/14.06.18-gene-therapy-for-parkinsons-clinical-progression.pdf\n\n \n\nTo contact us:Hardman & Co35 New Broad StreetLondonEC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCo\n Contacts:Dorothea Hill+44 20 7194 7626\n [email protected]\n \n \n\nHardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur resea...